Table 1.
Inhibitory activity of BA and derivatives on different cancer cells proliferation
|
Compound |
IC50(μM) a values against five human carcinoma cells |
||||
|---|---|---|---|---|---|
| MGC-803b | PC3c | A375d | Bcap-37e | A431f | |
| 1 |
41.2 ± 0.6 |
67.2 ± 0.5 |
> 100 |
> 100 |
15.7 ± 0.2 |
| 2a |
> 20 |
> 20 |
> 20 |
> 20 |
> 20 |
| 2b |
> 20 |
> 20 |
> 20 |
> 20 |
> 20 |
| 2c |
> 20 |
> 20 |
> 20 |
> 20 |
> 20 |
| 3a |
3.5 ± 0.5 |
5.6 ± 0.9 |
3.4 ± 0.1 |
5.5 ± 0.8 |
4.8 ± 0.2 |
| 3b |
3.4 ± 0.2 |
4.2 ± 0.2 |
6.0 ± 0.4 |
7.6 ± 0.5 |
5.7 ± 0.2 |
| 3c |
2.3 ± 0.2 |
4.6 ± 0.5 |
3.3 ± 0.4 |
3.6 ± 1.2 |
4.3 ± 0.3 |
| 3d |
7.6 ± 2.1 |
8.6 ± 0.2 |
12.4 ± 1.1 |
10.5 ± 0.5 |
11.8 ± 0.6 |
| 3e |
4.0 ± 0.9 |
3.8 ± 1.1 |
4.4 ± 0.5 |
3.0 ± 1.1 |
5.6 ± 0.1 |
| 3f |
4.3 ± 0.2 |
2.8 ± 0.4 |
2.7 ± 0.3 |
5.2 ± 0.1 |
3.5 ± 0.6 |
| 3g |
15.7 ± 0.5 |
13.4 ± 0.9 |
11.3 ± 0.6 |
16.2 ± 0.5 |
13.3 ± 0.4 |
| 3h |
12.7 ± 1.2 |
15.0 ± 0.5 |
11.6 ± 0.5 |
12.5 ± 0.5 |
9.6 ± 0.9 |
| 3i |
5.6 ± 0.4 |
7.9 ± 0.5 |
7.7 ± 0.3 |
6.8 ± 1.2 |
5.7 ± 0.2 |
| 3j |
7.6 ± 0.6 |
13.4 ± 0.7 |
12.8 ± 0.4 |
7.5 ± 0.6 |
10.5 ± 1.5 |
| 3k |
16.7 ± 0.5 |
17.1 ± 0.2 |
> 20 |
> 20 |
15.7 ± 0.7 |
| 3l |
11.8 ± 0.3 |
12.7 ± 1.5 |
13.9 ± 0.8 |
9.43 ± 0.8 |
7.0 ± 0.4 |
| 5a |
8.8 ± 0.8 |
10.1 ± 0.5 |
12.5 ± 0.6 |
9.4 ± 0.7 |
6.3 ± 0.8 |
| 5b |
13.4 ± 0.1 |
14.5 ± 0.4 |
15.3 ± 2.3 |
16.7 ± 0.8 |
12.9 ± 1.2 |
| 5c |
17.3 ± 0.4 |
> 20 |
> 20 |
> 20 |
> 20 |
| 5d |
> 20 |
18.9 ± 0.3 |
> 20 |
> 20 |
16.3 ± 0.1 |
| 5e |
> 20 |
> 20 |
> 20 |
> 20 |
> 20 |
| 5f |
15.4 ± 0.6 |
> 20 |
> 20 |
> 20 |
> 20 |
| HCPT |
29.1 ± 2.6 |
34.5 ± 1.5 |
27.8 ± 1.2 |
28.1 ± 1.0 |
23.4 ± 0.7 |
| ADM | 0.7 ± 0.2 | 0.6 ± 0.1 | 1.0 ± 0.6 | 1.2 ± 0.2 | 1.1 ± 0.1 |
a Agent concentration (micromolar) that inhibited cell growth by 50% 72 h after treatment; b Human gastric cancer; c Prostate cancer; d Malignant melanoma; e Breast cancer; f Epidermoid carcinoma.